This episode currently has no reviews.
Submit ReviewNvidia notching another day of losses, but the broader markets aren’t taking it too hard. How investors are handling the semi slide. Plus A big jump for one biopharma stock as Alnylam delivers promising new heart drug results. What the CEO had to say about the data, and the impact it could have on the space.
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review